[{"id":"d479d7a5-69ba-49e5-93fa-ae230286eb90","acronym":"CL1-95029-001","url":"https://clinicaltrials.gov/study/NCT05162755","created_at":"2021-12-17T17:31:24.245Z","updated_at":"2025-02-25T14:02:39.100Z","phase":"Phase 1","brief_title":"S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers","source_id_and_acronym":"NCT05162755 - CL1-95029-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e futuximab/modotuximab (S95026) • S95029 • Sym021"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 06/19/2025","study_completion_date":" 06/19/2025","last_update_posted":"2025-02-19"},{"id":"be12bd53-90a5-48e3-adf5-20a74ac186d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02540161","created_at":"2021-01-18T12:17:21.801Z","updated_at":"2024-07-02T16:36:42.324Z","phase":"Phase 2","brief_title":"Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT02540161","lead_sponsor":"Annick Desjardins","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e futuximab/modotuximab (S95026)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 07/10/2019","primary_completion_date":" 07/10/2019","study_txt":" Completion: 04/27/2020","study_completion_date":" 04/27/2020","last_update_posted":"2020-08-05"},{"id":"04c9b775-25b0-4b37-b256-7f6b7f8f9281","acronym":"Sym004-05","url":"https://clinicaltrials.gov/study/NCT02083653","created_at":"2021-01-18T09:36:24.980Z","updated_at":"2024-07-02T16:37:00.539Z","phase":"Phase 2","brief_title":"Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02083653 - Sym004-05","lead_sponsor":"Symphogen A/S","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • futuximab/modotuximab (S95026)"],"overall_status":"Completed","enrollment":" Enrollment 254","initiation":"Initiation: 03/06/2014","start_date":" 03/06/2014","primary_txt":" Primary completion: 10/24/2016","primary_completion_date":" 10/24/2016","study_txt":" Completion: 04/26/2017","study_completion_date":" 04/26/2017","last_update_posted":"2019-04-16"},{"id":"3fb73d98-86e6-4444-9d0d-6d32982297cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01117428","created_at":"2021-01-17T17:51:10.038Z","updated_at":"2024-07-02T16:37:06.104Z","phase":"Phase 1/2","brief_title":"Sym004 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01117428","lead_sponsor":"Symphogen A/S","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e futuximab/modotuximab (S95026)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 05/01/2015","study_completion_date":" 05/01/2015","last_update_posted":"2018-10-15"},{"id":"d44f8569-ac37-43ec-b763-3a102ecb6ab0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01417936","created_at":"2023-03-23T22:18:13.347Z","updated_at":"2024-07-02T16:37:06.111Z","phase":"Phase 2","brief_title":"Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy","source_id_and_acronym":"NCT01417936","lead_sponsor":"Symphogen A/S","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e futuximab/modotuximab (S95026)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2018-10-15"},{"id":"1c6cebdf-882a-4dc5-9f30-35f48564c3c1","acronym":"EMR 200637-001","url":"https://clinicaltrials.gov/study/NCT01955473","created_at":"2021-01-18T08:52:30.783Z","updated_at":"2025-02-25T14:49:45.799Z","phase":"Phase 1","brief_title":"Japanese Phase 1 Trial of Sym004 in Solid Tumors","source_id_and_acronym":"NCT01955473 - EMR 200637-001","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR amplification • EGFR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e futuximab/modotuximab (S95026)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 10/31/2013","start_date":" 10/31/2013","primary_txt":" Primary completion: 10/31/2015","primary_completion_date":" 10/31/2015","study_txt":" Completion: 10/31/2015","study_completion_date":" 10/31/2015","last_update_posted":"2017-08-23"}]